Investigating new treatments for high-risk neuroblastoma using GPC2 CAR T cells
Official title: GPC2 CARs in neuroblastoma: Mechanisms of resistance and efficacy of next-generation constructs
Funded at Children's Hosp of Philadelphia · NIH-11015892 · Data updated 2026-11-12
This study is looking at new ways to help children with high-risk neuroblastoma by using special immune cells that can better fight the cancer, and it aims to understand how the cancer can sometimes come back so that we can improve treatments and help kids live healthier lives.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $625,372 |
| NIH project number | 5R37CA282041-02 |
| Project ID | NIH-11015892 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 11 years old diagnosed with high-risk neuroblastoma.
✕Less likely to help
Patients with neuroblastoma who are not classified as high-risk or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on developing innovative therapies for children with high-risk neuroblastoma, a type of cancer that poses significant treatment challenges. The team is exploring the use of GPC2 chimeric antigen receptor (CAR) T cells, which are engineered to target a specific protein found on neuroblastoma cells. By understanding how these CAR T cells can be resisted by the cancer, the researchers aim to enhance their effectiveness and develop next-generation treatments. This work includes studying the mechanisms behind tumor relapse and finding ways to improve long-term outcomes for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for children with high-risk neuroblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using CAR T cell therapies for various cancers, indicating a potential for success with this novel approach in neuroblastoma.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Bosse, Kristopher R — Children's Hosp of Philadelphia
- Study coordinator: Bosse, Kristopher R
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.